Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2003
06/19/2003US20030114441 Heterocyclic anti-epileptogenic agents and methods of use thereof
06/19/2003US20030114434 Extended duration light activated cancer therapy
06/19/2003US20030114432 Antiinflammatory agents; rheumatic diseases; anticancer agents
06/19/2003US20030114430 Aqueous solution; controlling flocculation; oxidation resistance
06/19/2003US20030114427 Remedies and/or preventives for nervous system disorders
06/19/2003US20030114425 Tiamenidine
06/19/2003US20030114420 Anticancer agents, autoimmunine diseases, congestive heart failure, skin disorders, antiinflammatory agents
06/19/2003US20030114418 Analgesics; antiinflammatory and arthritic agents; osteoarthritis; rheumatic diseases; gastrointestinal, nervous system, respiratory disorders; wound healing agents; vision defects; kits
06/19/2003US20030114416 Analgesics; antiinflammatory, -arthritic agents; vision defects; gastrointestinal and uorgenital disorders; wound healing agents; kits
06/19/2003US20030114387 Gamma secretase inhibitors
06/19/2003US20030114382 Angiogenesis inhibition
06/19/2003US20030114375 Method for treating cystic fibrosis
06/19/2003US20030114368 Immunotoxins directed against malignant cells
06/19/2003US20030114365 Neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins; treating neurodegenrative disorders
06/19/2003US20030114364 Administering lactoferrin and glycomacropeptide; microbiocides
06/19/2003US20030113871 Glycoprotein hormones; human chorionic gonadotropin; carboxy terminal peptides (ctp); increaseing half life of polypeptides; antipernicious anemia drugs
06/19/2003US20030113844 Delayed rectifier potassium channel subunit
06/19/2003US20030113840 25 human secreted proteins
06/19/2003US20030113812 Evaluating modulators of neuron propagation; bone morphogenetic proteins; epidermal growth factors; erythropoietins; pleiotrophins; hepatocyte growth factors; somatomedins; nerve growth factors; interleukins
06/19/2003US20030113789 Protease peptides; anticarcinogenic agents; neurotransmitters; antidiabetic agents
06/19/2003US20030113775 7118, a human arginine N-methyltransferase family member and uses therefor
06/19/2003US20030113772 DNA encoding human alpha 1 adrenergic receptors and uses thereof
06/19/2003US20030113771 DNA encoding human alpha 1 adrenergic receptors and uses thereof
06/19/2003US20030113769 Aminooxy functionalized oligomers, oligomer arrays and methods of using them
06/19/2003US20030113763 Oligonucleotide compositions and their use to induce apoptosis
06/19/2003US20030113733 Transcription factors; nuclear localization peptides; human chorionic gonadotropic hormone(hCG); NF-kappaB/Rel proteins
06/19/2003US20030113393 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
06/19/2003US20030113389 Wherein dose of jojoba product provides simmondsin component in an amount greater than 0.05 gram/day
06/19/2003US20030113382 Causing cyclic GMP to increase in the neoplastic cells and exposing neoplastic cells to cisplatin derivative
06/19/2003US20030113377 Orally administered liquid compositions
06/19/2003US20030113366 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/19/2003US20030113359 Prosthetic device placed on the outside surface of the vessel or graft which then elutes antiproliferatives from a matrix
06/19/2003US20030113348 Non-laboratory strain used in the manufacture of a medicament for the oncolytic treatment of cancer; anticancer agents
06/19/2003US20030113331 An antagonist specifically binds to a denatured collagens; antitumor agents, antimetastasis agents; monoclonal antibodies; drug screening for denatured collagen antagonists
06/19/2003US20030113323 High mobility group proteins; diagnostic monitoring the severity or potential lethality of sepsis or septic shock, measuring the serum protein concentration of patient, treating weight loss or obesity
06/19/2003US20030113316 Stable lyophilized pharmaceutical formulation of IgG antibodies
06/19/2003US20030113315 Squalane containing ultra fine particles of burning residue of carbon and method for producing the same
06/19/2003US20030113306 Probiotic lactobacillus casei strains
06/19/2003US20030113303 Delivering a translocation stimulator to a target zone of the tissue, introducing human embryonic stem cells to the mammal for homing the human to the target zone of the tissue for effecting myogenesis at the target zone
06/19/2003US20030113278 Treatment of excessive radiation (e.g. sunburn) exposure
06/19/2003CA2784260A1 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
06/19/2003CA2470114A1 Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-heptanoic acid calcium salt (2:1)
06/19/2003CA2469893A1 Phenylalkynes
06/19/2003CA2469889A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
06/19/2003CA2469709A1 Substituted hydrazones as inhibitors of cyclooxygenase-2
06/19/2003CA2469670A1 Quinazoline derivatives for the treatment of abnormal cell growth
06/19/2003CA2469622A1 Substituted hydroxyethylamines
06/19/2003CA2469616A1 Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
06/19/2003CA2469596A1 Ureas of 2-aminobenzothiazoles as adenosine modulators
06/19/2003CA2469519A1 Deuterated substituted dihydrofuranones and medicaments containing these compounds
06/19/2003CA2469483A1 Hematopoietic cells from human embryonic stem cells
06/19/2003CA2469336A1 Guanidinium transport reagents and conjugates
06/19/2003CA2469316A1 Pyrimidine-based compounds useful as gsk-3 inhibitors
06/19/2003CA2469306A1 Methods and compositions for control of bone formation via modulation of sympathetic tone
06/19/2003CA2469161A1 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
06/19/2003CA2469147A1 Bis(cyanophenyl)methyl-triazole for use in prevention of breast cancer
06/19/2003CA2469000A1 Method for reducing acne or improving skin tone
06/19/2003CA2468994A1 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
06/19/2003CA2468892A1 Vitamin d analogues
06/19/2003CA2468659A1 Urea substituted imidazopyridines
06/19/2003CA2468544A1 Vanilloid receptor ligands
06/19/2003CA2468266A1 Substituted bicyclic pyrimidinones as a mitotic kinesin ksp inhibitors
06/19/2003CA2468174A1 Amide substituted imidazopyridines
06/19/2003CA2468164A1 Sulfonamido substituted imidazopyridines
06/19/2003CA2468156A1 Azolopyrimidinone compounds and their use
06/19/2003CA2467916A1 Mitotic kinesin inhibitors
06/19/2003CA2467802A1 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
06/19/2003CA2467689A1 Stabilization of hypoxia inducible factor (hif) alpha using inhibitors of hif prolyl hydroxylase
06/19/2003CA2467245A1 Prevention of flap necrosis in plastic surgery
06/19/2003CA2465759A1 Method for administering birb 796 bs
06/19/2003CA2465120A1 Composition and method for treating chronic allograft rejection
06/19/2003CA2464341A1 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
06/18/2003EP1319709A1 Disruption of the glutathione S-transferase-omega-1 gene
06/18/2003EP1319658A1 Imidazole derivatives or their salts
06/18/2003EP1319410A1 Use of micro-organisms for a directed delivery of substances to specific parts of the gut
06/18/2003EP1319402A1 Ige production inhibitors
06/18/2003EP1319182A2 G-csf analog compositions and methods
06/18/2003EP1319073A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding them, and uses thereof
06/18/2003EP1319071A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
06/18/2003EP1319064A2 Gsk3 polypeptides
06/18/2003EP1319025A2 Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse
06/18/2003EP1319015A2 Olfactory and pheromones g-protein coupled receptors
06/18/2003EP1319014A1 Antisense modulation of flip-c expression
06/18/2003EP1319007A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
06/18/2003EP1319005A2 Substituted azepino[4,5-b]indoline derivatives
06/18/2003EP1319004A2 Substituted azepino[4,5-b]indole derivatives
06/18/2003EP1319003A1 Xanthine phosphodiesterase v inhibitors
06/18/2003EP1319002A1 Alpha v integrin receptor antagonists
06/18/2003EP1319001A1 Pyrazolopyridines and pyrazolopyridazines as antidiabetics
06/18/2003EP1318997A1 Pyrazole compounds useful as protein kinase inhibitors
06/18/2003EP1318996A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
06/18/2003EP1318994A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
06/18/2003EP1318992A1 Imidazole derivatives as raf kinase inhibitors
06/18/2003EP1318991A1 Benzoic acid derivatives and uses thereof
06/18/2003EP1318988A2 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
06/18/2003EP1318985A2 4-amino-quinazolines
06/18/2003EP1318984A1 4-amino-quinazolines
06/18/2003EP1318981A2 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
06/18/2003EP1318980A2 Hydroxamate derivatives useful as deacetylase inhibitors
06/18/2003EP1318977A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
1 ... 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 ... 1564